The European Investment Bank helps the economy, creates jobs, promotes equality and improve lives for EU citizens and for people in developing countries.

**4 areas of focus**
- Innovation
- Climate
- Small businesses
- Infrastructure

**Supporting the fight against infectious diseases**

With InnovFin Infectious Diseases, the European Investment Bank funds innovators to develop vaccines, drugs, medical and diagnostic devices, and research infrastructure for combatting infectious diseases.

IDFF provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 and 75 million.

**UNIVERCELLS**

Univercells aims at increasing the availability of affordable vaccines and biotherapeutics to address global health challenges.

Our technology focuses on significantly reducing the infrastructure required for the production of biologics while simplifying and automating operations, fostering their dissemination at an affordable price.

Making biologics available and affordable to all!
Collaboration

EUR 20 million venture-debt financing

Fostering innovation by supporting small businesses

> The EIB provides stable long-term funding with a flexible repayment and interest structure
> Enabling innovative SMEs to focus on investing in innovation and growth

“Through its commitment to sponsor innovative fast-growing companies, the EIB demonstrates the willingness of the European Union to address important public health needs such as infectious diseases.”

Hugues Bultot
CEO Univercells

Sharing a societal mission against infectious diseases

> With the support of the EIB, Univercells will pursue its mission and develop a portfolio of viral vaccines
> The vaccines will be produced with the NevoLine™ biomanufacturing platform, delivering large quantities and at an affordable price

Vaccine portfolio

- Polio sIPV
- Measles, Rubella
- Rabies
- Global Health Vaccine

Produced with Univercells’ NevoLine platform

“The fight against infectious diseases ranks high on our policy agenda. We are proud to join Univercells and be able to support its pioneering research into such essential vaccines and for thriving to make them available to those countries in high needs.”

Jean-Christophe Laloux
Director General EIB